Year Founded
2021
Ownership
Public
Therapeutic Areas
Oncology
Stage
Preclinical
Modalities
RadiopharmaceuticalsNanobodyPeptidesSmall moleculeProtein therapeutics

Radiopharm Theranostics Limited General Information

Developing radiopharmaceutical products for diagnostic and therapeutic uses. DUNP19 has shown success in pre-clinical studies for LRRC15-expressing cancers.

Contact Information

Website
Primary Industry
[ "Biotech", "Pharma" ]
Corporate Office
Sydney, New South Wales
Australia

Drug Pipeline

DUNP19
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Radiopharm Theranostics Limited's pipeline data

Book a demo

Key Partnerships

Lantheus

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Radiopharm Theranostics Limited Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Radiopharm Theranostics Limited's complete valuation and funding history, request access »